» Articles » PMID: 32460168

SPOP Promotes Ubiquitination and Degradation of LATS1 to Enhance Kidney Cancer Progression

Overview
Journal EBioMedicine
Date 2020 May 28
PMID 32460168
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Emerging evidence has demonstrated that SPOP functions as an oncoprotein in kidney cancer to promote tumorigenesis by ubiquitination-mediated degradation of multiple regulators of cellular proliferation and apoptosis. However, the detailed molecular mechanism underlying the oncogenic role of SPOP in kidney tumorigenesis remains elusive.

Methods: Multiple approaches such as Co-IP, Transfection, RT-PCR, Western blotting, and animal studies were utilized to explore the role of SPOP in kidney cancer.

Findings: Here we identified LATS1, a critical component of the Hippo tumour suppressor pathway, as a novel ubiquitin substrate of SPOP. We found that LATS1 interacted with Cullin3, and depletion of Cullin 3 upregulated the abundance of LATS1 largely via prolonging LATS1 protein half-life. Mechanistically, SPOP specifically interacted with LATS1, and promoted the poly-ubiquitination and subsequent degradation of LATS1 in a degron-dependent manner. As such, over-expression of SPOP promoted cell proliferation partly through regulating cell cycle distribution in kidney cancer cells. Furthermore, SPOP also promoted kidney cancer cell invasion via degrading LATS1.

Interpretation: Our study provides evidence for a novel mechanism of SPOP in kidney cancer progression in part through promoting degradation of the LATS1 tumour suppressor.

Citing Articles

Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality.

Guo Q, Qin H, Chen Z, Zhang W, Zheng L, Qin T Genes Dis. 2025; 12(3):101311.

PMID: 40034124 PMC: 11875185. DOI: 10.1016/j.gendis.2024.101311.


The deubiquitinating enzyme ATXN3 promotes hepatocellular carcinoma progression by stabilizing TAZ.

Peng Y, Nie H, Kang K, Li X, Tao Y, Zhou Y Cancer Gene Ther. 2024; 32(1):136-145.

PMID: 39672915 DOI: 10.1038/s41417-024-00869-2.


Decoding the Role of O-GlcNAcylation in Hepatocellular Carcinoma.

Zhou X, Hang S, Wang Q, Xu L, Wang P Biomolecules. 2024; 14(8).

PMID: 39199296 PMC: 11353135. DOI: 10.3390/biom14080908.


FBXO22 promotes osteosarcoma progression via regulation of FOXO1 for ubiquitination and degradation.

Zhang H, Bai Y, Li J, Chen T, Shang G J Cell Mol Med. 2024; 28(16):e70021.

PMID: 39153212 PMC: 11330286. DOI: 10.1111/jcmm.70021.


SPOP regulates the expression profiles and alternative splicing events in human hepatocytes.

Dai J, Dong X, Chen Y, Xue W, Wang Q, Shang F Open Life Sci. 2023; 18(1):20220755.

PMID: 37941785 PMC: 10628592. DOI: 10.1515/biol-2022-0755.


References
1.
Salah Z, Melino G, Aqeilan R . Negative regulation of the Hippo pathway by E3 ubiquitin ligase ITCH is sufficient to promote tumorigenicity. Cancer Res. 2011; 71(5):2010-20. DOI: 10.1158/0008-5472.CAN-10-3516. View

2.
Geng C, He B, Xu L, Barbieri C, Eedunuri V, Chew S . Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc Natl Acad Sci U S A. 2013; 110(17):6997-7002. PMC: 3637757. DOI: 10.1073/pnas.1304502110. View

3.
Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z . 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006; 49(5):798-805. DOI: 10.1016/j.eururo.2005.11.035. View

4.
Sun Y . Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther. 2003; 2(6):623-9. View

5.
Mani R . The emerging role of speckle-type POZ protein (SPOP) in cancer development. Drug Discov Today. 2014; 19(9):1498-502. PMC: 4237012. DOI: 10.1016/j.drudis.2014.07.009. View